Nirmatrelvir Plus Ritonavir: First Approval

Yvette N Lamb, Yvette N Lamb

Abstract

Nirmatrelvir plus ritonavir (Paxlovid™; Pfizer) is a co-packaged combination of nirmatrelvir and ritonavir tablets, intended for co-administration and developed for the treatment and post-exposure prophylaxis of coronavirus disease 2019 (COVID-19). Nirmatrelvir is a peptidomimetic inhibitor of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) main protease, while ritonavir is a human immunodeficiency virus type 1 (HIV-1) protease inhibitor and CYP3A inhibitor. Nirmatrelvir plus ritonavir received its first conditional authorization in December 2021 in the United Kingdom, for the treatment of COVID-19 in adults who do not require supplemental oxygen and who are at increased risk for progression to severe COVID-19. In January 2022, nirmatrelvir plus ritonavir received authorization in the EU for use in the same indication. Nirmatrelvir plus ritonavir is authorized for emergency use in the USA. This article summarizes the milestones in the development of nirmatrelvir plus ritonavir leading to its first authorizations and approval for the treatment of COVID-19.

Conflict of interest statement

During the peer review process the manufacturer of the agent under review was offered an opportunity to comment on the article. Changes resulting from any comments received were made by the authors on the basis of scientific completeness and accuracy. Yvette Lamb is a salaried employee of Adis International Ltd/Springer Nature, and declares no relevant conflicts of interest. All authors contributed to the review and are responsible for the article content.

© 2022. The Author(s), under exclusive licence to Springer Nature Switzerland AG.

Figures

https://www.ncbi.nlm.nih.gov/pmc/articles/instance/9188515/bin/40265_2022_1692_Figa_HTML.jpg
Key milestones in the development of nirmatrelvir plus ritonavir. CHMP Committee for Medicinal Products for Human Use, COVID-19 coronavirus disease 2019, EUA emergency use authorization, SARS-CoV-2 severe acute respiratory syndrome coronavirus 2
https://www.ncbi.nlm.nih.gov/pmc/articles/instance/9188515/bin/40265_2022_1692_Figb_HTML.jpg
Chemical structure of nirmatrelvir

References

    1. Pfizer. NCT05047601. A study of a potential oral treatment to prevent COVID-19 in adults who are exposed to household member(s) with a confirmed symptomatic COVID-19 infection. 2022. . Accessed 21 Feb 2022.
    1. Pfizer. NCT05011513. Evaluation of protease inhibition for COVID-19 in standard-risk patients (EPIC-SR). 2022. . Accessed 21 Feb 2022.
    1. Pfizer. NCT04960202. EPIC-HR: study of oral PF-07321332/ritonavir compared with placebo in nonhospitalized high risk adults with COVID-19. 2022. . Accessed 21 Feb 2022.
    1. Fenton C, Lamb YN. COVID-19: state of the vaccination. Drugs Ther Perspect. 2021;37:508–518. doi: 10.1007/s40267-021-00869-4.
    1. Lamb YN. BNT162b2 mRNA COVID-19 vaccine: first approval. Drugs. 2021;81:495–501. doi: 10.1007/s40265-021-01480-7.
    1. Owen DR, Allerton CMN, Anderson AS, et al. An oral SARS-CoV-2 M(pro) inhibitor clinical candidate for the treatment of COVID-19. Science. 2021;374(6575):1586–1593. doi: 10.1126/science.abl4784.
    1. Macchiagodena M, Pagliai M, Procacci P. Characterization of the non-covalent interaction between the PF-07321332 inhibitor and the SARS-CoV-2 main protease. J Mol Graph Model. 2022;110:108042. doi: 10.1016/j.jmgm.2021.108042.
    1. Pavan M, Bolcato G, Bassani D, et al. Supervised Molecular Dynamics (SuMD) insights into the mechanism of action of SARS-CoV-2 main protease inhibitor PF-07321332. J Enzyme Inhib Med Chem. 2021;36(1):1646–1650. doi: 10.1080/14756366.2021.1954919.
    1. Pfizer Inc. PAXLOVID nirmatrelvir and ritonavir: US fact sheet for healthcare providers. 2021. . Accessed 21 Feb 2022.
    1. European Medicines Agency. Paxlovid 150 mg + 100 mg film-coated tablets: summary of product characteristics. 2022. . Accessed 21 Feb 2022
    1. Pfizer. Pfizer receives U.S. FDA Emergency Use Authorization for novel COVID-19 oral antiviral treatment [media release]. 23 Dec 2021. .
    1. UK Medicines and Healthcare products Regulatory Agency. Oral COVID-19 antiviral, Paxlovid, approved by UK regulator [media release]. Dec 31 2021. .
    1. Pfizer. Paxlovid 150 mg/100 mg film-coated tablets (PF-07321332/ritonavir): summary of product characteristics. 2021. . Accessed 21 Feb 2022.
    1. European Medicines Agency. COVID-19: EMA recommends conditional marketing authorisation for Paxlovid [media release]. 28 Jan 2022. .
    1. Australian Government Therapeutic Goods Administration. TGA provisionally approves two oral COVID-19 treatments, molnupiravir (LAGEVRIO) and nirmatrelvir + ritonavir (PAXLOVID) [media release]. 20 Jan 2022. .
    1. Pfizer Canada ULC. Paxlovid: Canadian product monograph. 2022. . Accessed 21 Feb 2022.
    1. Pfizer Canada. Pfizer receives Health Canada authorization for COVID-19 oral treatment [media release]. 18 Jan 2022. .
    1. Pfizer. Pfizer to provide U.S. government with an additional 10 million treatment courses of its oral therapy to help combat COVID-19 [media release]. 4 Jan 2022. .
    1. Pfizer. Pfizer to provide U.S. government with 10 million treatment courses of investigational oral antiviral candidate to help combat COVID-19 [media release]. 19 Nov 2021. .
    1. Pfizer. Pfizer to provide the United Kingdom an additional 2.5 million treatment courses of investigational oral antiviral candidate to help combat COVID-19 [media release]. 22 Dec 2021. .
    1. Pfizer. Pfizer and the Medicines Patent Pool (MPP) sign licensing agreement for COVID-19 oral antiviral treatment candidate to expand access in low- and middle-income countries [media release]. 16 Nov 2021. .
    1. Vangeel L, Chiu W, De Jonghe S, et al. Remdesivir, molnupiravir and nirmatrelvir remain active against SARS-CoV-2 Omicron and other variants of concern. Antivir Res. 2022;198:105252. doi: 10.1016/j.antiviral.2022.105252.
    1. Ullrich S, Ekanayake KB, Otting G, et al. Main protease mutants of SARS-CoV-2 variants remain susceptible to nirmatrelvir. Bioorg Med Chem Lett. 2022;62:128629.
    1. Hammond J, Leister-Tebbe H, Gardner A, et al. Oral nirmatrelvir for high-risk, nonhospitalized adults with Covid-19. NEJM. 2022 doi: 10.1056/NEJMoa2118542.
    1. Pfizer. Pfizer announces additional phase 2/3 study results confirming robust efficacy of novel COVID-19 oral antiviral treatment candidate in reducing risk of hospitalization or death [media release]. 15 Dec 2021. .

Source: PubMed

Sponsorer og samarbejdspartnere

Medicinske tilstande

Narkotikainterventioner

3
Abonner